Research never stops

Archive



Apr 05, 2017

Evotec achieves first milestone in Diabetes alliance with Sanofi

Hamburg, Germany 05 April 2017: Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept.

- read more
Mar 31, 2017

EvotecĀ“s partner Forge Therapeutics receives prestigious Carb-X research award

Hamburg, Germany - 31 March 2017: Evotec AG today announced that its partner Forge Therapeutics has received a research award from CARB-X of $ 8.8 m to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections.

- read more
Mar 28, 2017

Evotec fiscal year results 2016: Leading innovation efficiency & First-in-class drug discovery

Hamburg, Germany, 28 March 2017: Evotec AG today announced its financial results and corporate updates for the fiscal year ended 31 December 2016.

- read more
Mar 03, 2017

Great story - Short film

Hamburg, Germany – 03 March 2017:
Evotec AG and Business France today released their short film about Evotec’s research site in Toulouse, France, under the headline: “Evotec found Business in France – Great story, short film”. Please click here and enjoy.

- read more
Feb 21, 2017

Evotec AG: 'LAB282' awarded first projects

Hamburg, Germany, 21 February 2017:
Evotec AG is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford University, has made its first wave of awards, backing projects targeting cardiovascular diseases and infectious diseases.

- read more
Feb 09, 2017

Novo A/S becomes new long-term strategic shareholder in Evotec

Hamburg, Germany, 09 February 2017:
Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash.

- read more
Jan 26, 2017

Cyprotex, an Evotec company, expands into new UK facility at Alderley Park

Hamburg, Germany - 26 January 2017: Evotec AG today announced that Cyprotex, a company wholly owned by Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park.

- read more
Jan 19, 2017

Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma (Japan)

Jan 17, 2017

Evotec and MaRS Innovation establish strategic partnership to launch Fibrocor Therapeutics

Jan 12, 2017

HaplogenĀ“s novel antiviral target partnered with Evotec published in 'Nature'

Jan 09, 2017

Evotec and Eternygen to develop novel metabolic disease therapy